Robert A. Zivin

3.3k total citations · 1 hit paper
31 papers, 2.6k citations indexed

About

Robert A. Zivin is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Robert A. Zivin has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Immunology. Recurrent topics in Robert A. Zivin's work include Monoclonal and Polyclonal Antibodies Research (9 papers), T-cell and B-cell Immunology (5 papers) and Immunotherapy and Immune Responses (4 papers). Robert A. Zivin is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), T-cell and B-cell Immunology (5 papers) and Immunotherapy and Immune Responses (4 papers). Robert A. Zivin collaborates with scholars based in United States, Japan and Norway. Robert A. Zivin's co-authors include Jeffrey A. Bluestone, Danlin Xu, Julie Auger, Linda K. Jolliffe, William Hagopian, David Donaldson, David M. Harlan, Stephen E. Gitelman, Lesley Taylor and Kevan C. Herold and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Robert A. Zivin

31 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

2002 903 citations Julie Auger, Danlin Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert A. Zivin United States	25	1.1k	846	759	743	665	31	2.6k
Torkel Vang Norway	24	799 0.7×	1.5k 1.8×	1.6k 2.1×	286 0.4×	243 0.4×	39	3.0k
Jacques Marvaldi France	35	686 0.6×	292 0.3×	1.8k 2.4×	303 0.4×	431 0.6×	125	3.2k
Michael S. Lan United States	35	1.6k 1.4×	1.1k 1.3×	2.3k 3.1×	1.6k 2.1×	860 1.3×	98	4.6k
Valerie Quarmby United States	28	794 0.7×	1.3k 1.5×	1.6k 2.1×	96 0.1×	725 1.1×	64	3.5k
Souad Rahmouni Belgium	24	978 0.9×	1.1k 1.3×	1.6k 2.1×	376 0.5×	276 0.4×	56	2.8k
Heinrich Gausepohlꝉ Germany	24	300 0.3×	398 0.5×	1.4k 1.9×	264 0.4×	156 0.2×	33	2.4k
Heinz Lother Germany	21	628 0.6×	480 0.6×	1.6k 2.2×	112 0.2×	359 0.5×	33	2.7k
Steven K. Yoshinaga United States	21	1.0k 0.9×	919 1.1×	1.8k 2.4×	65 0.1×	344 0.5×	25	3.3k
Mark A. Tepper United States	19	227 0.2×	942 1.1×	859 1.1×	236 0.3×	284 0.4×	36	2.1k
Olga Gornik Croatia	28	495 0.5×	1.1k 1.3×	2.4k 3.1×	267 0.4×	120 0.2×	74	2.9k

Countries citing papers authored by Robert A. Zivin

Since Specialization

Citations

This map shows the geographic impact of Robert A. Zivin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Zivin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Zivin more than expected).

Fields of papers citing papers by Robert A. Zivin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Zivin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Zivin. The network helps show where Robert A. Zivin may publish in the future.

Co-authorship network of co-authors of Robert A. Zivin

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Zivin. A scholar is included among the top collaborators of Robert A. Zivin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Zivin. Robert A. Zivin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burnett, P. J., et al.. (2003). Fluorescence Imaging of Electrically Stimulated Cells. SLAS DISCOVERY. 8(6). 660–667. 12 indexed citations

Aono, Mitsuo, Yoonki Lee, Elfrida R. Grant, et al.. (2002). Apolipoprotein E Protects against NMDA Excitotoxicity. Neurobiology of Disease. 11(1). 214–220. 48 indexed citations

Grant, Elfrida R., et al.. (2002). Simultaneous Intracellular Calcium and Sodium Flux Imaging in Human Vanilloid Receptor 1 (VR1)-Transfected Human Embryonic Kidney Cells: A Method to Resolve Ionic Dependence of VR1-Mediated Cell Death. Journal of Pharmacology and Experimental Therapeutics. 300(1). 9–17. 46 indexed citations

Utset, Tammy O., Julie Auger, Donna Peace, et al.. (2002). Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.. PubMed. 29(9). 1907–13. 98 indexed citations

McMillian, Michael, Elfrida R. Grant, Zhong Zhong, et al.. (2001). Nile Red Binding to HepG2 Cells: An Improved Assay for In Vitro Studies of Hepatosteatosis. PubMed. 14(3). 177–190. 94 indexed citations

Burczynski, Michael E., Michael McMillian, J. Brandon Parker, et al.. (2001). Cytochrome P450 induction in rat hepatocytes assessed by quantitative real-time reverse-transcription polymerase chain reaction and the RNA invasive cleavage assay.. PubMed. 29(9). 1243–50. 27 indexed citations

Grant, Elfrida R., Stuart L. Emanuel, Daniel Benjamin, et al.. (2001). Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells22Abbreviations: AMPA, (±)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; NMDA, N-methyl-d-aspartate; MAP, mitogen-activated protein; ERK1/2, extracellular signal regulated kinase 1/2; MEK, mitogen-activated protein kinase kinase; JNK, Jun N-terminal kinase; NO, nitric oxide; CDK1, cyclin-dependent kinase I; PKA, protein kinase A; PKC, protein kinase C; CK1/2, casein kinase 1/2; EGFR, epidermal growth factor receptor; CaM-K, calcium/calmodulin-dependent kinase; ATRA, all-trans-retinoic acid; RT-PCR, reverse transcriptase-polymerase chain reaction; and CFDA, carboxyfluorescein diacetate.. Biochemical Pharmacology. 62(3). 283–296. 24 indexed citations

Thurmond, Robin L., Scott Wadsworth, Peter Schäfer, Robert A. Zivin, & John J. Siekierka. (2001). Kinetics of small molecule inhibitor binding to p38 kinase. European Journal of Biochemistry. 268(22). 5747–5754. 50 indexed citations

Haynes‐Johnson, Donna, et al.. (2001). Fluorescence Polarization Assay and SDS-PAGE Confirms Matrilysin Degrades Fibronectin and Collagen IV whereas Gelatinase: A Degrades Collagen IV but not Fibronectin. Connective Tissue Research. 42(2). 149–163. 13 indexed citations

10.

Xu, Danlin, Maria-Luisa Alegre, Annette L. Rothermel, et al.. (2000). In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies. Cellular Immunology. 200(1). 16–26. 177 indexed citations

11.

Woodle, E. Steve, Danlin Xu, Robert A. Zivin, et al.. (1999). PHASE I TRIAL OF A HUMANIZED, Fc RECEPTOR NONBINDING OKT3 ANTIBODY, huOKT3??1 (Ala-Ala) IN THE TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION. Transplantation. 68(5). 608–616. 140 indexed citations

12.

Richards, Jon, Julie Auger, Donna Peace, et al.. (1999). Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.. PubMed. 59(9). 2096–101. 35 indexed citations

13.

Woodle, E. Steve, Jeffrey A. Bluestone, Robert A. Zivin, et al.. (1998). Humanized, Nonmitogenic OKT3 Antibody, huOKT3γ(Ala-Ala): Initial Clinical Experience. Transplantation Proceedings. 30(4). 1369–1370. 30 indexed citations

14.

Johnson, Dana L., Francis X. Farrell, Francis P. Barbone, et al.. (1997). Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chemistry & Biology. 4(12). 939–950. 46 indexed citations

15.

Pulito, Virginia, Victoria Roberts, John R. Adair, et al.. (1996). Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. The Journal of Immunology. 156(8). 2840–2850. 41 indexed citations

16.

Alegre, Maria‐Luisa, Laura Peterson, Danlin Xu, et al.. (1994). A NON-ACTIVATING “HUMANIZED” ANTI-CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVO. Transplantation. 57(11). 1537–1543. 3 indexed citations

17.

Woodle, E. Steve, J. Richard Thistlethwaite, Linda K. Jolliffe, et al.. (1992). Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. The Journal of Immunology. 148(9). 2756–2763. 52 indexed citations

18.

Benfield, Pamela A., Robert A. Zivin, Linda Miller, et al.. (1984). Isolation and sequence analysis of cDNA clones coding for rat skeletal muscle creatine kinase.. Journal of Biological Chemistry. 259(23). 14979–14984. 61 indexed citations

19.

Zivin, Robert A., William A. Zehring, & Lucia B. Rothman‐Denes. (1981). Transcriptional map of bacteriophage N4. Journal of Molecular Biology. 152(2). 335–356. 36 indexed citations

20.

Zivin, Robert A., et al.. (1980). Physical map of coliphage N4 DNA. Virology. 104(1). 205–218. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact